These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6119925)

  • 41. Levobunolol and betaxolol. A double-masked controlled comparison of efficacy and safety in patients with elevated intraocular pressure.
    Long DA; Johns GE; Mullen RS; Bowe RG; Alexander D; Epstein DL; Weiss MJ; Masi RJ; Charap AD; Eto CY
    Ophthalmology; 1988 Jun; 95(6):735-41. PubMed ID: 3062529
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Comparison of the effect of a selective and a nonselective beta receptor blocker on the ischemic ST segment, lung function and stress-induced decrease in blood glucose].
    Brügmann U; Blasini R
    Herz; 1986 Feb; 11(1):55-61. PubMed ID: 2870014
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Initial therapy of essential hypertension: diuretic or beta blocker?
    Finnerty FA
    J Fam Pract; 1980 Aug; 11(2):199-205. PubMed ID: 6106039
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Timolol, dose response and duration of action.
    Zimmerman TJ; Kaufman HE
    Arch Ophthalmol; 1977 Apr; 95(4):605-7. PubMed ID: 322649
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Latanoprost : an update of its use in glaucoma and ocular hypertension.
    Perry CM; McGavin JK; Culy CR; Ibbotson T
    Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Atenolol eye drops in glaucoma: a double-masked, controlled study.
    Phillips CI; Gore SM; Macdonald MJ; Cullen PM
    Br J Ophthalmol; 1977 May; 61(5):349-53. PubMed ID: 326303
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The novel dopamine D-1 antagonist and D-2 agonist, SDZ GLC-756, lowers intraocular pressure in healthy human volunteers and in patients with glaucoma.
    Prünte C; Flammer J
    Ophthalmology; 1995 Sep; 102(9):1291-7. PubMed ID: 9097765
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dose-ranging study of the new beta-adrenergic antagonist nadolol in the treatment of essential hypertension.
    Frithz G
    Curr Med Res Opin; 1978; 5(5):383-7. PubMed ID: 26519
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Treatment with betaxolol and placebo eyedrops in patients with glaucoma and reactive airway diseases].
    Bleckmann H; Dorow P
    Klin Monbl Augenheilkd; 1987 Sep; 191(3):199-202. PubMed ID: 2890791
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Metipranolol 0.1%: effect of a single dose on the nycthemeral pressure curve in an eye with chronic primary open-angle glaucoma].
    Demailly P; Lecherpie F
    J Fr Ophtalmol; 1987; 10(6-7):447-9. PubMed ID: 2891739
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nadolol and placebo comparison study in the prophylactic treatment of migraine.
    Ryan RE; Ryan RE; Sudilovsky A
    Panminerva Med; 1982; 24(2):89-94. PubMed ID: 6128710
    [No Abstract]   [Full Text] [Related]  

  • 52. Beneficial effect of nadolol on anxiety-induced disturbances of performance in musicians: a comparison with diazepam and placebo.
    James I; Savage I
    Am Heart J; 1984 Oct; 108(4 Pt 2):1150-5. PubMed ID: 6148877
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Beta-adrenergic blockade by nadolol in control of ventricular tachyarrhythmias.
    Nademanee K; Schleman MM; Singh BN; Morganroth J; Reid PR; Stritar JA
    Am Heart J; 1984 Oct; 108(4 Pt 2):1109-15. PubMed ID: 6207720
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison between atenolol and nadolol in essential hypertension at rest and on exercise.
    Wilcox RG; Hampton JR
    Br J Clin Pharmacol; 1982 Jun; 13(6):841-6. PubMed ID: 6124268
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The efficacy of the combination of l-moprolol and dipivefrin in reducing the intraocular pressure in primary open-angle glaucoma or in ocular hypertension.
    Rossetti L; Barbieri P; Velati P; Bujtar E; Orzalesi N
    Graefes Arch Clin Exp Ophthalmol; 1994 Nov; 232(11):670-4. PubMed ID: 7843592
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cardiovascular effects of befunolol, betaxolol and timolol eye drops.
    Dorigo MT; Cerin O; Fracasso G; Altafini R
    Int J Clin Pharmacol Res; 1990; 10(3):163-6. PubMed ID: 1977708
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Peripheral beta-adrenergic blockade treatment of parkinsonian tremor.
    Foster NL; Newman RP; LeWitt PA; Gillespie MM; Larsen TA; Chase TN
    Ann Neurol; 1984 Oct; 16(4):505-8. PubMed ID: 6149724
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Timolol eye drops in the treatment of glaucoma and ocular hypertension. A multicentre study].
    Nielsen NV; Eriksen JS; Larsen G; Mortensen KK; Kemp A; Andersen F; Buhl H; Olsen J; Dalsgård C; Frandsen E; Vase I; Glissov B; Pugesgaard T; Jensen S; Heuer HE
    Ugeskr Laeger; 1981 Mar; 143(13):802-5. PubMed ID: 7027564
    [No Abstract]   [Full Text] [Related]  

  • 59. [Ocular hypotensive effect of 1% carteolol long-acting eye drops--a double-masked, randomized phase III study in ocular hypertension or primary open-angle glaucoma patients comparing long-acting carteolol eye drops vs. current product].
    Yamamoto T;
    Nippon Ganka Gakkai Zasshi; 2007 Jun; 111(6):463-72. PubMed ID: 17601060
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tremor: an alternative approach for investigating adrenergic mechanisms in thyrotoxicosis?
    Abila B; Lazarus JH; Kingswood JC; Marshall RW; Wilson JF; Richens A
    Clin Sci (Lond); 1985 Oct; 69(4):459-63. PubMed ID: 2864158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.